Certara Inc (CERT) reported Q3 2025 earnings, with earnings per share (EPS) of $0.14, surpassing Wall Street's consensus estimate of $0.11 by $0.03. Revenue matched expectations at $0.1 billion.
The results reflect Certara's position in the health care industry, where it provides software and technology-enabled services to drug developers. The company, headquartered in Radnor, Pennsylvania, employs 1,487 full-time staff and serves approximately 2,400 clients across 70 countries.
Certara will host its earnings conference call after market close to discuss these results and offer additional insights into its business performance.
With a market capitalization of $1,392.61 million and a P/E ratio of 174.49, Certara continues to enhance its offerings in biosimulation software and services, vital for drug discovery and regulatory submissions. Investors looking for more context on the quarter's performance can refer to the full earnings release and management commentary.
Upcoming earnings are scheduled for November 5, 2025, with an estimated EPS of $0.1113 and revenue expectations of $0.1 billion.